OBJECTIVE: We anticipated that the universal use of a standard @entity2399 infusion to prevent eclamptic @entity410 in preeclamptic @entity1 would result in alterations in circulating @entity1760 levels that were negatively correlated with the @entity1 's body mass index. We postulated that the highest failure rate with @entity410 prophylaxis would occur in @entity1 with the highest body mass index. MATERIALS AND METHODS: After discarding 6 @entity1 , this study was performed in 194 of 200 preeclamptic @entity1 admitted to our high risk pregnancy unit between February 2000 and August 2000, who were divided into four groups determined by body mass indices. A standard @entity2399 infusion protocol (loading dose 4.5 g/15 minutes followed by 1.8 g/hour) was administered to 194 preeclamptic @entity1 . One hundred and thirty-eight severe preeclamptic @entity1 received @entity2399 during both antepartum and postpartum periods. The remaining 56 @entity1 only received the therapy during the postpartum period. Serial serum @entity1760 levels of each groups were recorded and compared. RESULTS: The 1.8 g infusion rate produced acceptable @entity1760 levels in the majority of @entity1 but most were in the lower 50% of the therapeutic range. Levels were lowest in @entity1 with high body mass indices (this group recorded most of the subtherapeutic levels, particularly when @entity1 were infused antepartum). Apart from 13 referred @entity1 who had convulsed prior to admission no @entity3036 occurred during the antepartum period while @entity410 occurred in nine @entity1 during the postpartum period. Two hours after the initiation of the therapy, @entity1760 levels were inversely related to the body mass index (BMI) both during the ante- and postpartum periods (Prepartum; group I: 5.97 mg/dl, group II: 4.90 mg/dl, group III: 4.35 mg/dl, group IV: 3.88 mg/dl; Postpartum; group I: 5.89 mg/dl, group II: 5.71 mg/dl, group III: 4.82 mg/dl and group IV: 4.61 mg/dl, Table 4). Although the lowest levels were detected in @entity1 with high body mass indices, in contrast to our hypothesis, @entity410 occurred in four @entity1 with low body mass indices. Furthermore therapeutic serum @entity1760 levels were detected in three of these @entity1 . There was no association between treatment failures and body mass or with @entity1760 levels. CONCLUSION: The infusion regimen described herein resulted in therapeutic levels in the majority of @entity1 that correlated inversely with body mass index. However most levels fell within the lower range of what many studies consider "therapeutic" suggesting that maintenance infusion rates of at least 2-2.5 g/hour would be more appropriate. This would be particularly true in @entity1 with body mass indices exceeding 30, where subtherapeutic levels occurred most frequently. The study's limited power prevents conclusions on outcomes but what is of interest is that eclamptic @entity410 did not correlate with either body mass index or circulating plasma @entity1760 levels.

The use of standard dose of magnesium sulphate in prophylaxis of XXXX : do body mass index alterations have any effect on success?

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'eclamptic seizures', 'convulsions'] @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate'] @entity3036 :: ('MESH:D004461', 'Disease') :: ['eclampsia'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity410 :: (MESH:D012640,Disease) :: ['eclamptic seizures']
